4//SEC Filing
Latour Wouter 4
Accession 0001209191-18-010565
CIK 0000072444other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 8:21 PM ET
Size
23.7 KB
Accession
0001209191-18-010565
Insider Transaction Report
Form 4
Vaxart, Inc.VXRT
Latour Wouter
DirectorPresident and Chief Executive
Transactions
- Award
Stock Option (right to buy)
2018-02-13+9,442→ 9,442 totalExercise: $8.03Exp: 2021-11-03→ Common Stock (9,442 underlying) - Award
Stock Option (right to buy)
2018-02-13+18,120→ 18,120 totalExercise: $17.49Exp: 2025-07-23→ Common Stock (18,120 underlying) - Award
Stock Option (right to buy)
2018-02-13+23,651→ 23,651 totalExercise: $4.07Exp: 2027-06-24→ Common Stock (23,651 underlying) - Award
Stock Option (right to buy)
2018-02-13+6,536→ 6,536 totalExercise: $8.03Exp: 2021-06-29→ Common Stock (6,536 underlying) - Award
Stock Option (right to buy)
2018-02-13+13,256→ 13,256 totalExercise: $6.49Exp: 2023-08-08→ Common Stock (13,256 underlying) - Award
Stock Option (right to buy)
2018-02-13+10,731→ 10,731 totalExercise: $12.98Exp: 2026-03-25→ Common Stock (10,731 underlying) - Award
Stock Option (right to buy)
2018-02-13+14,908→ 14,908 totalExercise: $8.03Exp: 2024-05-08→ Common Stock (14,908 underlying)
Footnotes (8)
- [F1]Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split").
- [F2]On June 29, 2011, Reporting Person was granted an option to purchase 324,600 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 6,536 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $8.03 (as adjusted for the Stock Split). This option is fully vested.
- [F3]On November 3, 2011, Reporting Person was granted an option to purchase 468,900 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,442shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $8.03 (as adjusted for the Stock Split). This option is fully vested.
- [F4]On August 8, 2013, Reporting Person was granted an option to purchase 658,323 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 13,256 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested.
- [F5]On May 8, 2014, Reporting Person was granted an option to purchase 740,448 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 14,908 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $8.03 (as adjusted for the Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of May 8, 2014 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
- [F6]On July 23, 2015, Reporting Person was granted an option to purchase 900,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.35 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 18,120 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $17.49 (as adjusted for the Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of June 30, 2015 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
- [F7]On March 25, 2016, Reporting Person was granted an option to purchase 533,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.26 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 10,731 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $12.98 (as adjusted for the Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of March 24, 2016 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
- [F8]On June 24, 2017, Reporting Person was granted an option to purchase 1,174,729 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.08 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 23,651 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $4.07 (as adjusted for the Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of June 14, 2017 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
Documents
Issuer
Vaxart, Inc.
CIK 0000072444
Entity typeother
Related Parties
1- filerCIK 0001652203
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 8:21 PM ET
- Size
- 23.7 KB